The prevalence of inflammatory bowel disease in an Israeli Arab population

To determine the prevalence of inflammatory bowel disease among the 1.5million Arab residents in Israel who represent 20% of the total population. Family physicians in all Arab towns and villages were contacted to obtain information on patients with inflammatory bowel disease. Relevant clinical data...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2013-06, Vol.7 (5), p.e159-e163
Main Authors: Zvidi, Ibrahim, Fraser, Gerald M., Niv, Yaron, Birkenfeld, Shlomo
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Arabs
Arthralgia - complications
Arthritis - complications
Child
Colitis, Ulcerative - complications
Colitis, Ulcerative - drug therapy
Colitis, Ulcerative - ethnology
Crohn Disease - drug therapy
Crohn Disease - ethnology
Crohn Disease - surgery
Crohn's disease
Epidemiology
Family aggregation
Female
Humans
Inflammatory bowel disease
Israel - epidemiology
Maintenance Chemotherapy
Male
Mesalamine - therapeutic use
Middle Aged
Prevalence
Smoking - ethnology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Ulcerative colitis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the prevalence of inflammatory bowel disease among the 1.5million Arab residents in Israel who represent 20% of the total population. Family physicians in all Arab towns and villages were contacted to obtain information on patients with inflammatory bowel disease. Relevant clinical data were retrieved and updated to December 31, 2009. Information was obtained from 23/71 municipalities approached (representing 200,000 out of 1.5million Arabs). There were 64 confirmed cases of Crohn's disease indicating a prevalence rate of 32/100,000. The rate of smoking within this cohort was lower than in the general population (1.5% vs. 40%; P
ISSN:1873-9946
1876-4479
DOI:10.1016/j.crohns.2012.07.026